Matt Gline (L) and Vivek Ramaswamy

Vivek Ra­maswamy and Matt Gline swoop in­to Nas­daq on the wings of Jim Mom­tazee's SPAC with a $7B-plus Roivant de­but ready to do some deals

Sev­en years af­ter found­ing Roivant Sci­ences as an up­start con­tender in the world of biotech cre­ation, Vivek Ra­maswamy and his re­cent­ly anoint­ed CEO Matt Gline are glid­ing in­to Nas­daq on the gild­ed wings of a cash-heavy SPAC.

In a care­ful­ly craft­ed SPAC pact aimed at wed­ding new in­vestors at Montes Archimedes Ac­qui­si­tion Corp. with a syn­di­cate of in­vestors com­ing back to re-up for the next round of com­pa­ny build­ing, they’ve as­sem­bled a fresh $611 mil­lion in fi­nanc­ing for Roivant — $411 mil­lion held in trust from the in­vestors in MAAC with a fresh $200 mil­lion from the syn­di­cate.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.